FDA批准BridgeBio的Attruby 用于ATTR心脏氨基质病,将死亡人数和住院人数减少42%。 FDA approves BridgeBio's Attruby for ATTR cardiac amyloidosis, reducing deaths and hospitalizations by 42%.

BridgeBio Pharma's AttrubyTM 已经获得林业发展局的批准,可以治疗患有ATTR-心血管炎的成年人,减少心血管死亡和住院。 BridgeBio Pharma's Attruby™ has received FDA approval for treating adults with ATTR-cardiac amyloidosis, reducing cardiovascular death and hospitalizations. 它是几乎完全稳定甲状腺素的第一个产品,在第三阶段的研究中显示出重大效益。 It is the first product to stabilize transthyretin near completely, showing significant benefits in a Phase 3 study. Attruby将死亡率和住院率减少了42%,生活质量得到改善。 Attruby reduced death and hospitalization by 42% and improved quality of life. 这项批准还触发了BridgeBio公司5亿美元的付款。 The approval also triggers a $500 million payment for BridgeBio.